Equities Analysts Set Expectations for NovoCure Q1 Earnings

NovoCure Limited (NASDAQ:NVCR) – Equities researchers at HC Wainwright raised their Q1 2026 earnings per share estimates for NovoCure in a note issued to investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now anticipates that the medical equipment provider will earn ($0.36) per share for the quarter, up from their previous forecast of ($0.54). HC Wainwright currently has a “Buy” rating and a $49.00 target price on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for NovoCure’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.15) EPS, FY2027 earnings at ($0.62) EPS, FY2028 earnings at $0.49 EPS, FY2029 earnings at $2.45 EPS and FY2030 earnings at $4.79 EPS.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. NovoCure had a negative return on equity of 38.82% and a negative net margin of 20.79%.The firm had revenue of $174.35 million during the quarter, compared to analysts’ expectations of $174.40 million. During the same quarter last year, the business posted ($0.61) EPS. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year.

Several other brokerages have also commented on NVCR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Wedbush reiterated a “neutral” rating and set a $18.00 target price on shares of NovoCure in a report on Thursday, January 15th. Finally, Evercore set a $20.00 price objective on shares of NovoCure in a report on Monday, January 5th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $26.93.

NovoCure Stock Performance

NovoCure stock opened at $13.67 on Monday. NovoCure has a 52 week low of $9.82 and a 52 week high of $21.55. The stock has a fifty day moving average price of $12.73 and a 200 day moving average price of $12.67. The company has a current ratio of 1.55, a quick ratio of 1.50 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $1.56 billion, a P/E ratio of -11.20 and a beta of 0.71.

Institutional Trading of NovoCure

Several hedge funds have recently added to or reduced their stakes in NVCR. Empowered Funds LLC bought a new stake in shares of NovoCure during the 4th quarter worth about $33,000. SJS Investment Consulting Inc. purchased a new position in shares of NovoCure in the third quarter worth approximately $41,000. Kestra Advisory Services LLC acquired a new stake in NovoCure during the 4th quarter valued at $49,000. Larson Financial Group LLC raised its position in NovoCure by 662.1% during the third quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock valued at $53,000 after buying an additional 3,562 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in shares of NovoCure in the second quarter worth approximately $88,000. Institutional investors own 84.61% of the company’s stock.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.